Off-label rituximab (Rituxan) led to fewer relapses over 2 years than dimethyl fumarate (Tecfidera) in people with early relapsing-remitting multiple sclerosis (MS), the phase III RIFUND-MS trial ...
The investigational drug diroximel fumarate (Vumerity, Biogen/Alkermes) showed statistically superior gastrointestinal (GI) tolerability compared with dimethyl fumarate (Tecfidera, Biogen) in patients ...
Treatment with dimethyl fumarate, compared with teriflunomide, is associated with better clinical outcomes in patients with relapsing-remitting multiple sclerosis (MS), according to new research. Time ...
DALLAS -- Large proportions of patients starting on dimethyl fumarate (Tecfidera) for multiple sclerosis appear to need additional medications to manage the drug's gastrointestinal and other adverse ...
Credit: Getty Images. Treatment with diroximel fumarate was associated with significantly fewer days of key gastrointestinal symptoms, according to topline results from a phase 3 study evaluating the ...
DUBLIN and CAMBRIDGE, Mass., July 30, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced positive topline results from EVOLVE-MS-2, a large, randomized, ...
CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new data to support the consistent, long-term benefits of treatment with TECFIDERA® (dimethyl fumarate) over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results